2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3246

Does Loss of a Community Walking Speed Lead to More Symptoms of Depression in Knee OA? a Trajectory Analysis from the Osteoarthritis Initiative
Abstract Number: 1791

Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events? a Case-Control Study
Abstract Number: 851

Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?
Abstract Number: 2518

Does the Cytokine Pattern, Including the IL23 – IL17 Immune Axis, Change in Pregnant Women with Psoriatic Arthritis?
Abstract Number: 659

Does the Inclusion of Extra-Articular Manifestations Improve Validity of the Self-Administered Comorbidity Questionnaire Modified for Spondyloarthritis (SpA-SCQ)? Results from ASAS-Comospa
Abstract Number: 1678

Does the Level of Disease Control Achieved with Biologics Influence Overall Costs for Health Care and Work Loss in RA?
Abstract Number: 42

Does the Risk of Mortality in Patients with RA Change over Time or Disease Duration?
Abstract Number: 1995

Does the Risk of Serious Infections Among Elderly RA Patients Differ By Age of Disease Onset?
Abstract Number: 106

Does the Timing of Phenotype Assessment Influence Association Results in Pharmacogenetics Studies of Anti-TNF Response in Rheumatoid Arthritis?
Abstract Number: 2074

Dominant Chilblain Lupus Due to an Activating Mutation of Sting – Suppression of Constitutive Type I Interferon Activation By JAK Inhibition
Abstract Number: 758

Dominican Patients with Systemic Lupus Erythematosus Residing in New York City Have a Higher SLICC/ACR Damage Index Than Those in the Dominican Republic
Abstract Number: 2206

Dopamine Pathway and Bone Metabolism in Arthritis
Abstract Number: 3094

Dose Adjustment of Anakinra (Kineret®) Based on Clinical Response in Patients with Severe Cryopyrin-Associated Periodic Syndromes
Abstract Number: 2149

Dose Reduction Compared with Standard Dosing for Maintenance of Remission in Patients with Spondyloarthropathies and Clinical Remission with Anti-TNF: A Randomised Real-Life Trial
Abstract Number: 49

Dose Relationship Between Oral Glucocorticoids and TNF Inhibitors and the Risk of Hospitalized Infectious Events Among Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].